Gallbladder Cancer Recurrence
Gallbladder cancer recurrence remains one of the top concerns for patients who have undergone treatment. Recurrence means that the cancer returns – either to the gallbladder, surrounding tissue, or elsewhere in the body – warranting continued treatment.
When gallbladder cancer recurrence is detected, treatment options are once again considered. In most cases, especially when the gallbladder has already been removed, the priority becomes chemotherapy and supportive care to relieve symptoms. Novel therapies as part of clinical trials may also be recommended to attempt to combat the spread of the cancer.
One of the frustrating aspects of cancer recurrence of any kind is that there is little evidence that can help predict when and if the patient’s cancer will return. With that said, most physicians agree there are certain behaviors that can have a positive impact on the patient’s overall health in the aftermath of cancer treatment. Some of these lifestyle changes can include:
- Maintaining a healthy body weight – this includes avoiding obesity but also getting your weight back to normal after cancer treatment, which can take time as the appetite gradually returns
- Avoiding smoking – as the impact of nicotine and other carcinogenic products are well known for the effect they have on the body
- Eating well – avoiding fatty foods and making a commitment to clean living can make a big difference in a person’s energy levels and lifestyle
Furthermore, it is extremely important to be diligent with your follow-up care after gallbladder cancer treatment. While these appointments won’t necessarily prevent a recurrence, they help ensure that early warning signs can be detected as soon as possible, allowing treatment to begin immediately.
At Moffitt Cancer Center, our Gastrointestinal Oncology Program offers a number of treatments for new cases of gallbladder cancer and recurrence, and we have been designated by the National Cancer Institute as a Comprehensive Cancer Center, which speaks to our expertise in delivering a variety of leading treatments and clinical trials.